Close Menu

Biodesix

The collaboration is focused on using Biognosys' HRM mass spec technology to facilitate Biodesix's companion diagnostic work.

The $11 million is in addition to $27 million that the company raised previously in a Series E financing, bringing the total proceeds to $38 million.

The company has received similar coverage decisions from other payors in recent months.

The decision means that UnitedHealthcare's members will have access to Biodesix's test for advanced NSCLC as a covered benefit.

The proteomics test to guide treatment of non-small cell lung cancer will be covered for 3.4 million patients in Maryland, DC, and Virginia.

The study found that using Veristrat to guide patient therapy decreased the total lifetime direct medical cost per patient by $135.

The company cited as likely applications development of tests for guiding therapy in late-stage patients and support of drug development efforts.

The deal will leverage Inivata's technology platform and Biodesix's development and commercialization capabilities in the US.

The company plans to launch a PCR-based test for measuring three genes in the plasma of lung cancer patients and is also at work on an NGS-based panel.

Biodesix will use the investment to continue development of its blood-based molecular diagnostic technology platform and test menu.

Pages

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.